AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21853543 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-hyperintensities on brain MRI in children aged 2-7 years
Number of subjects: 162
Study 20168020 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora intervention (community health worker) for 9 weeks
Number of subjects: 98
Study 20168020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 16940720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 518
Study 16940720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 14974656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivicaine
Number of subjects: 164
Study 14974656 — intervention group
Group type: COMPARATOR
Intervention: Normal saline control
Number of subjects: 164
Study 11682660 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily for 4 weeks
Number of subjects: 10
Study 11682660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9002081 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula
Number of subjects: 45
Study 9002081 — intervention group
Group type: COMPARATOR
Intervention: Whey predominant formula
Number of subjects: 45
Study 8206188 — intervention group
Group type: COMPARATOR
Intervention: External subcutaneous insulin pumps (EXT)
Number of subjects: 0
Study 8206188 — intervention group
Group type: COMPARATOR
Intervention: Implantable programmable insulin pumps (IMP)
Number of subjects: 0
Study 3305224 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (CT) - monthly courses of cytosine arabinoside (ARA‐C) alternatingly combined with daunorubicin or thioguanine or cyclophosphamide
Number of subjects: 167
Study 3305224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (CIT) - intradermal injections of 10(10) neuraminidase‐treated viable allogeneic blasts per immunization interspersed between CT courses
Number of subjects: 167
Study 28833652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical vitamin C applied twice daily
Number of subjects: 18
Study 28833652 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 27133311 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAPT) - aspirin plus clopidogrel plus cilostazol; cilostazol loading dose of 100 mg bid for 1 week
Number of subjects: 113
Study 27133311 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel; no cilostazol
Number of subjects: 113
Study 27133311 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPT in antiplatelet-naïve subgroup
Number of subjects: 113
Study 27133311 — intervention group
Group type: COMPARATOR
Intervention: DAPT in antiplatelet-naïve subgroup
Number of subjects: 113
Study 27133311 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPT in antiplatelet-treated subgroup
Number of subjects: 113
Study 27133311 — intervention group
Group type: COMPARATOR
Intervention: DAPT in antiplatelet-treated subgroup
Number of subjects: 113
Study 24749639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of young infants
Number of subjects: 94
Study 24749639 — intervention group
Group type: COMPARATOR
Intervention: Nulliparous females
Number of subjects: 94
Study 24469880 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ASA
Number of subjects: 234
Study 24469880 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel
Number of subjects: 234
Study 20451174 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic suturing
Number of subjects: 41
Study 20451174 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic drills
Number of subjects: 41
Study 20451174 — intervention group
Group type: EXPERIMENTAL
Intervention: Open suturing
Number of subjects: 41
Study 20451174 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) drills
Number of subjects: 41
Study 20451174 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical laparoscopic trainer
Number of subjects: 41
Study 17535502 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-control model of job strain
Number of subjects: 60
Study 16189315 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group (drain for 24 hours)
Number of subjects: 552
Study 16189315 — intervention group
Group type: COMPARATOR
Intervention: Undrained group (no drain)
Number of subjects: 552
Study 12915835 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg per day for 28 days) plus dexamethasone (0.15 mg/kg per day for 5 days)
Number of subjects: 123
Study 12915835 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus dexamethasone
Number of subjects: 123
Study 10507210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% TiF4
Number of subjects: 32
Study 10507210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% TiF4
Number of subjects: 32
Study 10507210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% TiF4
Number of subjects: 32
Study 10507210 — intervention group
Group type: EXPERIMENTAL
Intervention: APF
Number of subjects: 32
Study 10507210 — intervention group
Group type: COMPARATOR
Intervention: NaF
Number of subjects: 32
Study 10507210 — intervention group
Group type: COMPARATOR
Intervention: Control (de-ionised water)
Number of subjects: 32
Study 8961912 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine plus benzathine penicillin for 24 months
Number of subjects: 0
Study 8961912 — intervention group
Group type: COMPARATOR
Intervention: Colchicine alone
Number of subjects: 0
Study 1933520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmion
Number of subjects: 54
Study 1933520 — intervention group
Group type: COMPARATOR
Intervention: Haemaccel
Number of subjects: 54
Study 7049709 — intervention group
Group type: EXPERIMENTAL
Intervention: supidimide 2 x 200 mg per day
Number of subjects: 40
Study 7049709 — intervention group
Group type: EXPERIMENTAL
Intervention: supidimide
Number of subjects: 40
Study 7049709 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 6360575 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg bd
Number of subjects: 12
Study 6360575 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg qd
Number of subjects: 12
Study 6360575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6360575 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil bd
Number of subjects: 12
Study 6360575 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil qd
Number of subjects: 12
Study 30037361 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide MDI 320 μg
Number of subjects: 147
Study 30037361 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide MDI 160 μg
Number of subjects: 147
Study 30037361 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 147
Study 25829062 — intervention group
Group type: EXPERIMENTAL
Intervention: rotatable handle piece (rot-HP)
Number of subjects: 57
Study 25829062 — intervention group
Group type: COMPARATOR
Intervention: standard laparoscopic (fixed) handle piece
Number of subjects: 57
Study 25829062 — intervention group
Group type: EXPERIMENTAL
Intervention: higher working height (WH)
Number of subjects: 57
Study 25829062 — intervention group
Group type: EXPERIMENTAL
Intervention: lower working height (WH)
Number of subjects: 57
Study 25829062 — intervention group
Group type: EXPERIMENTAL
Intervention: both rot-HP and standard handle
Number of subjects: 57
Study 24886034 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based working memory training for 45 minutes, 25 sessions over 5 weeks
Number of subjects: 90
Study 24886034 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of the program, identical in duration but non-adaptive in difficulty
Number of subjects: 90
Study 23023322 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT) prior to surgery for SUI or MUI
Number of subjects: 176
Study 23023322 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT)
Number of subjects: 176
Study 23023322 — intervention group
Group type: EXPERIMENTAL
Intervention: Research question underlying proposed studies
Number of subjects: 176
Study 20350429 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal lavage (2-3 times daily)
Number of subjects: 58
Study 20350429 — intervention group
Group type: COMPARATOR
Intervention: Control (no lavage)
Number of subjects: 58
Study 18565596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 mug)
Number of subjects: 10
Study 18565596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15990777 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 44
Study 15990777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12431891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program by outreach visitors lasting 21 months
Number of subjects: 62
Study 10417667 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 306
Study 10417667 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (inactivated polio vaccine)
Number of subjects: 306
Study 9395611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous homeopathic complex preparations containing Echinacea angustifolia D1 (study 1)
Number of subjects: 134
Study 9395611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous homeopathic complex preparations containing Echinacea angustifolia D4 (study 5)
Number of subjects: 134
Study 9395611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcoholic extracts of roots of E. purpurea (studies 2 and 3a)
Number of subjects: 134
Study 9395611 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of E. pallida roots (study 3b)
Number of subjects: 134
Study 9395611 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of E. purpurea herb (study 4)
Number of subjects: 134
Study 9395611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control groups)
Number of subjects: 134
Study 1799918 — intervention group
Group type: EXPERIMENTAL
Intervention: bis-glycino iron II
Number of subjects: 38
Study 1799918 — intervention group
Group type: COMPARATOR
Intervention: ferrous sulfate
Number of subjects: 38
Study 7451778 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-blister fluid (SBF) taken from dual skin reactions 30 or 60 min after allergen injection
Number of subjects: 17
Study 7451778 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-blister fluid (SBF) taken from LCR areas 180 or 300 min after antigen testing
Number of subjects: 17
Study 7451778 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of SBF from untested skin
Number of subjects: 17
Study 7451778 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar volumes of autologous heparin-plasma or serum
Number of subjects: 17
Study 29192549 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP XR-OS (15 mL)
Number of subjects: 42
Study 29192549 — intervention group
Group type: COMPARATOR
Intervention: Adderall XR (30 mg capsule)
Number of subjects: 42
Study 30454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO)
Number of subjects: 79
Study 30454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish
Number of subjects: 79
Study 30454883 — intervention group
Group type: COMPARATOR
Intervention: Lean fish
Number of subjects: 79
Study 30454883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 30156314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosravuconazole L-lysine ethanolate (100 mg RVCZ, n = 101)
Number of subjects: 153
Study 30156314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 153
Study 27374360 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-platelet rich fibrin (L-PRF) with allogenous bone graft
Number of subjects: 28
Study 27374360 — intervention group
Group type: COMPARATOR
Intervention: Allogenous bone graft with resorbable collagen membrane
Number of subjects: 28
Study 24496492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisection plus reaching task (BR‐task)
Number of subjects: 0
Study 24496492 — intervention group
Group type: COMPARATOR
Intervention: Bisection task (B‐task)
Number of subjects: 0
Study 22216840 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV vaccine (20 μg of glycoprotein D from HSV‐2 with alum and 3‐O‐deacylated monophosphoryl lipid A as an adjuvant)
Number of subjects: 8323
Study 22216840 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 8323
Study 22216840 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis A vaccine, 720 ELISA units)
Number of subjects: 8323
Study 20713883 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (NSAID)
Number of subjects: 0
Study 20713883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17390103 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lorazepam
Number of subjects: 12
Study 17390103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 12
Study 17390103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16298697 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home, nurse-delivered, symptom-focused teaching/counseling intervention
Number of subjects: 41
Study 16298697 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (usual care)
Number of subjects: 41
Study 12575567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongmai Yizhi capsule (TMYZC)
Number of subjects: 50
Study 12575567 — intervention group
Group type: COMPARATOR
Intervention: Hydergine (control)
Number of subjects: 50
Study 9396450 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-frequency domain method (TF) using smoothed pseudo-Wigner-Ville transformation (SPWVT) for heart rate variability analysis during tilt.
Number of subjects: 0
Study 7943782 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM)
Number of subjects: 44
Study 7943782 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 44
Study 2452123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of rIFN‐gamma/m2 body surface administered daily for 28 days
Number of subjects: 8
Study 2452123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg of rIFN‐gamma administered daily for 28 days
Number of subjects: 8
Study 2452123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.25 mg and 0.10 mg of rIFN‐gamma)
Number of subjects: 8
Study 30736102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise protocol during hospitalization, 15 to 30 minutes daily, supervised by an exercise specialist.
Number of subjects: 42
Study 30736102 — intervention group
Group type: COMPARATOR
Intervention: Control group remained physically inactive during hospitalization.
Number of subjects: 42
Study 26785098 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault-injured youth
Number of subjects: 964
Study 26785098 — intervention group
Group type: COMPARATOR
Intervention: Unintentionally injured youth
Number of subjects: 964
Study 26785098 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault-injured youth with 1 previous psychiatric ED visit
Number of subjects: 964
Study 26467316 — intervention group
Group type: EXPERIMENTAL
Intervention: Stories DVD + routine clinical treatment
Number of subjects: 300
Study 26467316 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical treatment
Number of subjects: 300
Study 23148280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 20
Study 23148280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21170557 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amygdalohippocampectomy (SAH)
Number of subjects: 179
Study 21170557 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe resection (TLR)
Number of subjects: 179
Study 21170557 — intervention group
Group type: COMPARATOR
Intervention: Both SAH and TLR
Number of subjects: 179
Study 19648168 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 1106
Study 19648168 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha plus cytarabine
Number of subjects: 1106
Study 17399871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone (with no wiring)
Number of subjects: 65
Study 17399871 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy with flexor carpi radialis suspension
Number of subjects: 65
Study 14760660 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training (ten repetitions of all six tasks on the Minimally Invasive Surgical Trainer‐Virtual Reality (MIST‐VR))
Number of subjects: 16
Study 14760660 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 16
Study 14760660 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study 11214135 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 40
Study 11214135 — intervention group
Group type: COMPARATOR
Intervention: Gastroscopy (Control)
Number of subjects: 40
Study 9165565 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg tablet
Number of subjects: 26
Study 9165565 — intervention group
Group type: COMPARATOR
Intervention: 1-mg/ml oral solution
Number of subjects: 26
Study 8222874 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg three times daily for 10-21 days
Number of subjects: 57
Study 8222874 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg three times daily for 10-21 days
Number of subjects: 57
Study 8222874 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 57
Study 8222874 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB)
Number of subjects: 57
Study 8222874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EA and EB
Number of subjects: 57
Study 3517712 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol therapy
Number of subjects: 4
Study 3517712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30989339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless standard femoral stems (Group A)
Number of subjects: 50
Study 30989339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless short stems (Group B)
Number of subjects: 50
Study 28657697 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 124
Study 28657697 — intervention group
Group type: COMPARATOR
Intervention: Medication (MED)
Number of subjects: 124
Study 27631248 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 41
Study 27631248 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional stroke rehabilitation program only)
Number of subjects: 41
Study 24831764 — intervention group
Group type: EXPERIMENTAL
Intervention: Open irrigated tip catheter - Surround Flow™ (N=30)
Number of subjects: 60
Study 24831764 — intervention group
Group type: COMPARATOR
Intervention: 8-mm-tip catheter (N=30)
Number of subjects: 60
Study 21782351 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 73
Study 21782351 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 73
Study 19767322 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS diaries
Number of subjects: 72
Study 19767322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper diaries
Number of subjects: 72
Study 19767322 — intervention group
Group type: EXPERIMENTAL
Intervention: Online diaries
Number of subjects: 72
Study 19767322 — intervention group
Group type: COMPARATOR
Intervention: Retrospective questionnaire
Number of subjects: 72
Study 18281662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1,000 mg/m(2) on days 1, 8, and 15 every 28 days
Number of subjects: 153
Study 18281662 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days
Number of subjects: 153
Study 18281662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 153
Study 18281662 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 153
Study 15813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated accelerometry-based system for estimating initial contact (IC) and terminal contact (TC) timing
Number of subjects: 18
Study 12646750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 600 mg levofloxacin plus five topical instillations before surgery
Number of subjects: 0
Study 12646750 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and oral administration of levofloxacin
Number of subjects: 0
Study 10676545 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching staff development intervention
Number of subjects: 0
Study 10676545 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching practices
Number of subjects: 0
Study 8686718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic treatment (ciprofloxacin and rifampin)
Number of subjects: 85
Study 8686718 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic treatment (oxacillin or vancomycin plus gentamicin)
Number of subjects: 85
Study 8446254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (5 x 2 g intravenously, n = 10)
Number of subjects: 23
Study 8446254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (960 mg orally b.i.d., n = 8)
Number of subjects: 23
Study 8446254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 23
Study 3785783 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (4500-5000 rad tumor dose in five to 6.5 weeks bilaterally to the groins and midplane of the pelvis)
Number of subjects: 114
Study 3785783 — intervention group
Group type: COMPARATOR
Intervention: Pelvic node resection
Number of subjects: 114
Study 31653175 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication effect score
Number of subjects: 263
Study 31479411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lines
Number of subjects: 10
Study 31479411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dashed
Number of subjects: 10